Blood Transfusions for Sickle Cell Disease
Blood Transfusions for Sickle Cell DiseaseSkip to the navigationTreatment OverviewDuring a blood transfusion, a person (the
recipient) receives healthy blood from another person (the donor). The donated
blood is carefully screened for diseases before it is used. Before receiving a
blood transfusion, the recipient's blood is analyzed closely (using
blood type) to make sure the donor blood is a close
match to the recipient's. Blood is transfused into an arm vein
slowly over 1 to 4 hours (except in an emergency when blood is transfused more
quickly). Blood transfusions can: - Treat a sudden or short-term condition related
to
sickle cell disease.
- Treat severe
complications of sickle cell disease.
- Prevent complications of
sickle cell disease.
- Lower the risk of
stroke in infants and children.
Blood transfusions aren't usually used to treat
uncomplicated
painful events or mild to moderate
anemia. What To Expect After TreatmentFollowing a blood transfusion, doctors
keep a close watch on the person for any negative reactions. Your doctor might check for iron buildup in the body
(iron overload). This can happen when a person gets many transfusions. Why It Is DoneA blood transfusion lowers the amount
of
hemoglobin S red blood cells in the body. When there
are fewer sickled hemoglobin S cells in the bloodstream, they are less likely
to build up and block blood vessels. Blood transfusion also
increases the number of normal red blood cells in the body, increasing the
supply of oxygen to the body. AnemiaSome sudden complications of sickle cell
disease cause the body's red blood cell count to drop to life-threatening
levels (severe anemia). When severe, these conditions (including
splenic sequestration,
acute chest syndrome, and
aplastic crisis) can be fatal if not treated with
blood transfusions. Chronic severe anemia from kidney failure may
need treatment with periodic blood transfusions. SurgeryAfter having
general anesthesia and surgery, people who have sickle
cell disease are at risk for sickling-related problems and acute chest
syndrome. Blood transfusions before surgery can prevent or treat these
complications. Red blood cell sickling-related complications (vaso-occlusion)Blood transfusions can treat acute chest
syndrome and leg ulcers. Frequent blood transfusions may help
prevent strokes in children who already had a stroke or are at high risk for a
first stroke.footnote 1 How Well It WorksBlood transfusion is an effective and proven treatment for some severe complications of
sickle cell disease.footnote 2 Blood transfusions
reduce the risk of some complications of sickle cell disease and reduce symptoms of severe anemia. Blood transfusion may help prevent a first stroke in children who have sickle cell
disease. Transfusions can help prevent a second stroke in most children. But some children
who get repeat transfusions will still have a second stroke.footnote 3 RisksA person receiving many blood transfusions will
gradually collect too much iron in the body (iron overload). Very high levels
of iron can lead to
hemochromatosis, which can be fatal if untreated.
Iron
chelation treatment can help rid the body of excess
iron. A person receiving repeat blood transfusions may develop
antibodies to the donor blood. This is called
alloimmunization. Alloimmunization makes repeated
transfusions more difficult. It occurs in about 1 out of 4 people who have sickle
cell disease and who get frequent transfusions.footnote 4 A transfusion reaction can result from mismatched blood type. And it may
occur immediately or days later. An acute
transfusion reaction ranges from mild (fever, chills, and rash) to severe
(shock, severe anemia, painful event, and death). Donated blood is carefully screened for diseases before it
is used. It is very rare for a disease to be transmitted through donated blood. What To Think AboutIf you have repeated blood
transfusions, you'll have routine testing for iron buildup in your body.
Though blood transfusions are an effective treatment for sickle
cell disease complications, they are only used selectively. The risks of
hemochromatosis and alloimmunization from repeat transfusions makes this
procedure more suitable for severe and high-risk conditions. Complete the special treatment information form (PDF)(What is a PDF document?) to help you understand this treatment. ReferencesCitations- Goldstein LB, et al. (2010). Guidelines for the primary prevention of stroke: A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. Published online December 2, 2010 (doi: 10.1161/STR.0b013e3181fcb238). Also available online: http://stroke.ahajournals.org/content/42/2/517.full.
- Wang WC (2009). Sickle cell anemia and other sickling syndromes. In JP Greer et al., eds., Wintrobe's Clinical Hematology, 12th ed., pp. 1038-1082. Philadelphia: Lippincott Williams and Wilkins.
- National Heart, Lung, and Blood Institute, National Institutes of Health (2002). The Management of Sickle Cell Disease (NIH Publication No. 02-2117). Available online: http://www.nhlbi.nih.gov/health/prof/blood/sickle/.
- Steinberg MH (2016). Sickle cell disease and other hemoglobinopathies. In L Goldman, A Shafer, eds., Goldman-Cecil Medicine, 25th ed., vol. 2, pp. 1095-1104. Philadelphia: Saunders.
CreditsByHealthwise Staff Primary Medical ReviewerE. Gregory Thompson, MD - Internal Medicine Adam Husney, MD - Family Medicine Martin J. Gabica, MD - Family Medicine Specialist Medical ReviewerMartin Steinberg, MD - Hematology Current as ofMarch 9, 2017 Current as of:
March 9, 2017 Goldstein LB, et al. (2010). Guidelines for the primary prevention of stroke: A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. Published online December 2, 2010 (doi: 10.1161/STR.0b013e3181fcb238). Also available online: http://stroke.ahajournals.org/content/42/2/517.full. Wang WC (2009). Sickle cell anemia and other sickling syndromes. In JP Greer et al., eds., Wintrobe's Clinical Hematology, 12th ed., pp. 1038-1082. Philadelphia: Lippincott Williams and Wilkins. National Heart, Lung, and Blood Institute, National Institutes of Health (2002). The Management of Sickle Cell Disease (NIH Publication No. 02-2117). Available online: http://www.nhlbi.nih.gov/health/prof/blood/sickle/. Steinberg MH (2016). Sickle cell disease and other hemoglobinopathies. In L Goldman, A Shafer, eds., Goldman-Cecil Medicine, 25th ed., vol. 2, pp. 1095-1104. Philadelphia: Saunders. Last modified on: 8 September 2017
|
|
|
|
|
|